(Sharecast News) - Contract development and manufacturing firm Oxford Biomedica said on Tuesday that it expects to report a strong rise in full year revenues, but signalled that underlying profitability would only be modest despite a one‑off boost from its US acquisition.
Oxford Biomedica expects FY25 revenues to increase by around...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE